Pharma PLI draws ₹46,744 crore, but China’s API import share rises to 73.7%
India’s pharma PLI schemes have exceeded investment targets and expanded local API, device and bulk-drug capacity. Yet China’s share of India’s API, KSM and intermediate imports increased from 68.2% in FY21 to 73.7% in FY25, underscoring continued supply-chain dependence.
What happened
Government of India · India’s pharma PLI schemes drew Rs 46,744 crore of investment, exceeding targets and expanding domestic API and device capacity. However,
Key facts
- Rs 46,744 crore PLI investment as of June 2026
- Rs 17,275 crore investment target
- Rs 4.03 lakh crore total sales
- Rs 2.57 lakh crore exports
- 1.21 lakh jobs
- Rs 5,210.74 crore bulk-drug PLI investment
- Rs 4,330 crore committed bulk-drug investment
- 39 commissioned projects covering 28 APIs
- 11.5% investment growth from December 2025 to June 2026
- 20.2% cumulative sales growth
- China API/KSM/intermediate imports: Rs 18,646 crore in FY21 and Rs 27,032 crore in FY25
- China import share: 68.2% in FY21 and 73.7% in FY25
- 191 of 726 APIs, KSMs and intermediates produced in India for the first time
- 57 high-end medical devices produced domestically
- 3 bulk-drug parks approved
Why this matters
Prioritize partnerships, acquisitions or long-term offtake deals in Indian API, KSM and intermediate manufacturing to convert policy-supported capacity growth into lower import exposure.
What to watch
- China API/KSM export controls, anti-dumping actions, environmental inspections or freight-rate spikes.
- Monthly import data showing sustained further growth in China share or sharp increases in API/KSM unit prices.
- NPPA price revisions, shortage notifications or changes to the National List of Essential Medicines.
- PLI scheme revisions linking incentives to domestic value addition, minimum capacity utilization or government procurement.
- Commercial commissioning and USFDA/CDSCO approvals for Indian API and bulk-drug-park facilities.
- Inventory days and gross-margin commentary from Indian drug formulators, distributors and organized pharmacy chains.
- Audit exposure to high-volume essential medicines whose APIs, KSMs or intermediates are predominantly China sourced.
- Increase safety-stock and dual-sourcing requirements for antibiotics, pain management, diabetes, cardiovascular and chronic-care products with constrained supplier bases.
- Track whether branded-generic manufacturers pass API inflation through to distributors, hospitals and pharmacy retailers or absorb it through margin compression.
- Favor supplier contracts with price-adjustment clauses, supply guarantees and origin-level traceability rather than relying on country-of-invoice data.
- For pharmacy retailers, expand substitution protocols and customer communication for equivalent generics if specific SKUs face availability gaps.
- Monitor PLI beneficiaries for actual commercial output, utilization rates, regulatory approvals and customer offtake rather than announced capex alone.